Effects of chelerythrine and erlotinib on SK-MES-1 xenograft mice model.

<p>A, B and C. NOD SCID mice were injected with 4×10⁶cells suspended in 0.1ml of PBS subcutaneously into the left chest. Treatments (erlotinib: 50mg/kg, o. p. daily; cheleryhine; 10mg/kg, o. p. daily; or a combination of both drugs; and DMSO was used as the control group) with drugs were initiated when the tumor volume reached about 150mm³. Tumor volume and mice weight were recorded every two days. At the end of the 14 day treatment, the mice were sacrificed, and the xenograft tumors were taken out and weighed. N = 6; Mean ± SEM; (E+C vs Control was considered very significant at Day14, **p = 0.0012; Che vs Control was also significant, *p<0.05; Two-way ANOVA). D. mice weights were monitored during the treatment. E. normal histologically appearance on the organs from a representative mouse treated with a combination of chelerythrine and erlotinib.